Drug class
Selective aldosterone synthase inhibitor (CYP11B2 inhibitor); antihypertensive
Mechanism of action
Inhibits human aldosterone synthase, reducing aldosterone production and plasma aldosterone concentrations. This reduces renal sodium and water retention and lowers blood pressure; baxdrostat is more potent and selective for aldosterone synthase than the related cortisol-synthesis enzyme 11β-hydroxylase.
General use cases
- Treatment of hypertension in adults who are not adequately controlled on other agents, in combination with other antihypertensive drugs, under the US FDA BAXFENDY indication (initial US approval 2026)
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
